Miist Therapeutics Announces $7M In Funding to Develop Instant-Acting Medicine
Summary
Phase 1 results for MST-01 demonstrate the speed of Miists therapies, with patients achieving 92% symptom relief in only 2 minutes post dosing.Drawing on the experience of Miists CTO Jeff Schuster, a Berkeley Physics PhD and aerosol drug delivery veteran, the company has developed a proprietary inhaler that generates sterile aqueous drug particles small enough to reach the peripheral lung. Miist has clinically validated that this approach achieves peak plasma drug levels in less than 30 seconds, approximately 100x faster than the absorption of a pill. Before joining forces and setting up their Bay Area HQ, Dalton Signor (CEO) was recruited by Entrepreneur First and started building Miist full time in London, Eric Ezerins (Head of R&D) had begun a career in ocular biotherapeutic drug delivery, and Jeff Schuster (CTO) had already established himself as one of the top technical minds in inhalation drug delivery. Miist Therapeutics applies a physics-based approach to develop inhaled therapies that are faster acting and more effective than todays standard of care. The companys core technology is an inhaler that uses ultrasonic vibration to generate and deliver 2-micron aqueous drug particles to the peripheral lung, where they are instantly absorbed into the bloodstream.